Champiat, Stéphane
Ferrara, Roberto
Massard, Christophe
Besse, Benjamin
Marabelle, Aurélien
Soria, Jean-Charles
Ferté, Charles
Article History
First Online: 25 October 2018
Competing interests
: S.C. has received honoraria from AstraZeneca, BMS, Janssen, MSD, Novartis and Roche. B.B. has received institutional grants for clinical and translational research from AstraZeneca, BMS, Boehringer-Ingelheim, Inivata, Lilly, Loxo, OncoMed, Onxeo, OSE Pharma, Pfizer, Roche-Genentech, Sanofi-Aventis and Servier. J-.C.S. has received honoraria from MedImmune/AstraZeneca, Pierre Fabre, Roche, Sanofi, Servier and Tarveda, and became a full-time employee of Medimmune/AstraZeneca after this article was commissioned. C.F. became a full-time employee of Medimmune/AstraZeneca after this article was commissioned. The other authors declare no competing interests.